Search Results

Addex Therapeutics, a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, reported its Q1 2024 financial results and provided a corporate update.

Addex Therapeutics announced that CEO, Tim Dyer, will present at the Bio€quity Europe 2024 conference taking place May 12 - 14, 2024 at the Kursaal Congress Center in San Sebastián, Spain.

Addex Therapeutics, a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced that its 2024 Annual General Meeting will take place on Friday June 28, 2024, at 11:00 am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva.

Addex Therapeutics announced the launch of Neurosterix, a company focused on developing allosteric modulators for the treatment of underserved neurological disorders.

Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, reported its full-year 2023 financial results for the period ended December 31, 2023 and provided a corporate update.

Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced that it will issue its Full-Year 2023 Financial Results on April 18, 2024.

Addex Therapeutics announced that CEO, Tim Dyer, will present at the Bio-Europe Spring 2024 conference taking place March 18 - 20, 2024 in Barcelona, Spain.

Johnson & Johnson and Addex Therapeutics’ epilepsy hopeful ADX71149 did not meet its primary endpoint of time to reach baseline seizure count in a mid-stage trial, as the partners look to determine the next steps for the program.